X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IAMA-6 is an orally administered small molecule therapeutic designed to directly target and inhibit NKCC1-associated neuronal hyperexcitability. It is under phase 1 clinical development for the treatment of Autism & Epilepsy.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
IAMA-6 is an orally administered small molecule therapeutic targeting NKCC1. Its clinical trial application is approved after the preclinical studies for the treatment of autism and epilepsy.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
Evotec will provide IAMA with preclinical and clinical services to support the anticipated Phase 1 clinical trial to investigate IAMA's lead program IAMA-6, a small molecule therapeutic targeting NKCC1 for the treatment of autism and epilepsy.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Evotec
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 02, 2023
Details:
The collaboration aims to investigate the efficacy of selective chloride modulator, IAMA-6, in reducing neuronal excitability and hippocampal activity in human tissue with epilepsies and neurodevelopmental disorders, including Dravet syndrome, FCD, and Rett syndrome.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sapienza University of Rome
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 10, 2023
Details:
PsychoGenics will evaluate the anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which restore the physiological hyperpolarizing and inhibitory GABAergic transmission in a preclinical model of Dravet syndrome.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PsychoGenics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2023
Details:
Under the agreement, PsychoGenics will evaluate the preclinical anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which aims to reduce intracellular chloride concentration and restore the physiological hyperpolarizing and inhibitory GABAergic transmission.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: PsychoGenics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 25, 2022
Details:
IAMA-6 is a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
IAMA-6 is a preclinical stage, a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission.
Lead Product(s): IAMA-6
Therapeutic Area: Neurology Product Name: IAMA-6
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Under the collaboration with the IIT-Istituto Italiano di Tecnologia (Italian Institute of Technology), they will design and profile new classes of compounds targeting cation cotransporters in the CNS area.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Italian Institute of Technology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
